|
|
Article: Abraxis BioScience and Biocon Limited Announce Approval of ABRAXANE in India for the Treatment of Breast Cancer.
- Article from:
- Business Wire
- Article date:
- October 18, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LOS ANGELES & BANGALORE, India -- Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, and Biocon Limited, India's leading biotechnology company, today announced the approval to market ABRAXANE([R]) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer by the country's Drug Controller General. Commercial introduction of ABRAXANE in the Indian market is expected in 2008 following the completion of the appropriate importation certifications.
"The approval of ABRAXANE for the treatment of breast cancer in India is an important step in ...